APOB and metabolic dysfunction-associated steatotic liver disease: In addition to the involvement of ApoB in atherosclerosis and CVD, ApoB-related dyslipidemia is linked to another global epidemic, nonalcoholic fatty liver disease (NAFLD), which affects around 20%–30% of the adult population in Western countries (6).